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Abstract: Diabetes is an important health condition for the aging population; at least 20% of 
patients over the age of 65 years have diabetes, and this number can be expected to grow rapidly 
in the coming decades. Rosiglitazone, a drug in the thiazolidinedione class which targets insulin 
resistance, was approved by drug regulatory bodies based on its ability to improve glycemic 
control nearly ten years ago. The greatest long-term risk in diabetes is cardiovascular disease 
with macrovascular disease being the cause of as much as 80% of mortality. More recently 
the cardiovascular safety of rosiglitazone was brought to center stage following several meta-
analyses and the unplanned interim analysis of the RECORD trial. As opposed to pioglitazone, 
current evidence points to rosiglitazone having a greater risk of myocardial ischemic events 
than placebo, metformin, or sulfonylureas. A thiazolidinedione class effect however seems 
apparent with respect to the increased risk for fractures and congestive heart failure. Clinical 
trial evidence on rosiglitazone therapy in the elderly is limited. The available evidence is mainly 
related to observational cohort studies. Most of the trial evidence relates to a younger population 
and therefore these data can not be directly extrapolated to an older population. The effects of 
the thiazolidinedione drug class remain incompletely understood.
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Introduction
Significant advances in diabetes care have been made over the past two decades with a 
mounting body of evidence underscoring the benefits of glycemic control,1 lipid and blood 
pressure management1–4 and contributing to our current understanding of comprehensive 
diabetes care which addresses multiple risk factors.5 Despite this, the residual risk remains 
substantial with the risk of cardiovascular disease (CVD) in the diabetic population 
being two- to four-fold higher compared to the general population and as many as 80% 
of all people with diabetes will die from macrovascular complications.6 Diabetes is an 
important health condition for the aging population; at least 20% of patients over the 
age of 65 years have diabetes, and this number can be expected to grow rapidly in the 
coming decades.7 Despite numerous blood glucose-lowering medications being currently 
available and with several more drug classes having been recently developed, there is 
a dearth of high-quality studies that provide head-to-head comparisons of the ability of 
these medications to achieve the currently recommended glycemic levels.8
One such class of drugs, namely thiazolidinediones (TZDs), has been marketed for the 
last decade. Rosiglitazone (Avandia; GlaxoSmithKline, Brentford, UK) is a TZD, a class 
of drugs which targets insulin resistance. The TZDs are selective ligands of the nuclear 
transcription factor peroxisome-proliferator-activated receptor-γ (PPARγ).9 The PPARs Vascular Health and Risk Management 2009:5 390
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are a subfamily of the nuclear-receptor superfamily which 
regulates gene expression in response to ligand binding.10 The 
TZDs sensitize end organs to insulin through their action on 
PPARγ which make them potentially useful agents to lower 
blood glucose concentrations.
This discovery was followed by several clinical trials 
which proved the efficacy of this new class of antiglycemic 
agents.11–16 The first TZD, troglitazone, was approved in 
1997 but it was subsequently withdrawn from the market 
in March 2000 because of hepatotoxicity. In 1999, the 
two currently available PPAR agonists, rosiglitazone and 
pioglitazone were approved in the United States. These had 
less hepatotoxicity but were associated with hemodilution, 
anemia, weight gain, edema, and increased risk for heart 
failure. More recently, after nearly a decade of use, the Food 
and Drug Administration (FDA) concluded in July 2007 
that the use of rosiglitazone for the treatment of T2DM was 
associated with a greater risk of myocardial ischemic events 
than placebo, metformin, or sulfonylureas.17
PPARs
Since the discovery of PPARs by Isselman and Green in 1990, 
these molecules have been shown to play a major role in a 
diverse group of processes and pathological conditions asso-
ciated with aging, inflammation, immunity, obesity, cancer, 
and fertility.18,19 PPARs regulate gene transcription by two 
mechanisms namely transactivation and transrepression.9 In 
transactivation, which is DNA-dependent, PPARγ forms a 
heterodimer with the retinoid X receptor (RXR) and recog-
nizes specific DNA response elements called PPAR response 
elements (PPRE) in the promoter region of target genes. This 
results in transcription of PPARγ target genes. In transrepres-
sion, PPARs can repress gene transcription by negatively 
interfering with other signal-transduction pathways, such 
as the nuclear factor-κB (NFκB) signaling pathway, in a 
DNA-binding-independent manner.
Three PPAR isotypes, namely, PPARα, PPARβ (or δ), and 
PPARγ have been identified. They display differential tissue 
distribution with PPARα being expressed mainly in the liver, 
skeletal, and cardiac muscle and in the endothelial cells and 
smooth-muscle cells of the vascular wall. It regulates genes 
that influence lipoprotein metabolism and fatty acid uptake 
and oxidation as well as production of inflammatory mark-
ers. Fibrates such as fenofibrate, bezafibrate, ciprofibrate, and 
gemfibrozil act as full or partial PPARα agonists.20 PPARβ 
is expressed in many tissues, with the highest expression in 
the skin, brain, and adipose tissue. PPARγ is expressed most 
abundantly in adipose tissue but is also found in pancreatic 
beta cells, vascular endothelium, and macrophages.21 PPARγ 
was originally identified as a central regulator of gene expres-
sion and differentiation in adipose cells.22
Thiazolidinediones: Mechanism 
of action
Both nondiabetic subjects and those with type 2 diabetes 
mellitus (T2DM) show increased insulin-stimulated glucose 
uptake in peripheral tissues as well as increased hepatic insu-
lin sensitivity (the ability of insulin to suppress endogenous 
glucose production) and insulin sensitivity in adipose tissue 
(measured from the ability of insulin to suppress free fatty 
acid concentrations).9,23,24 The mechanisms by which insu-
lin sensitization occurs are thought to involve either direct 
action on fatty acid uptake and storage in adipose tissue 
(also known as the fatty steal hypotheses) or indirectly via 
its action adipokines such adiponectin.25 The free fatty acid 
storage in adipose tissue as opposed to liver and skeletal most 
likely exerts a protective effect on these tissues. In addition, 
advantageous effects on the beta cells of the pancreas may 
occur by inhibiting glucolipotoxicity.26 Taken together, the 
mechanisms of action are complex and multifold and the 
many effects of TZDs in various tissues make it impossible 
to define all the exact mechanisms underlying their insulin-
sensitizing effects in vivo in humans.9
Rosiglitazone and cardiovascular 
disease:   A timeline of events
Cardiovascular disease is a very common complication of 
diabetes in up to 80% of all people with diabetes who die 
from macrovascular complications. It would therefore be 
prudent to evaluate the effects of any hypoglycemic agent on 
cardiovascular outcomes. Furthermore, improving glycemic 
control does not equate to improved CVD outcomes and in fact 
may lead to the contrary.27 Following marketing in 1999 in the 
United States and 2000 in Europe, it became clear that both rosi-
glitazone and pioglitazone increased the risk of congestive heart 
failure (CHF). A World Health Organization (WHO) report 
in 2003 suggested that TZDs might increase risk for cardiac 
disease which prompted GlaxoSmithKline (GSK) to submit 
preliminary pooled analyses of its cardiovascular safety to the 
FDA in 2005.28 The FDA’s review of these and other data led 
to the first rosiglitazone label warnings about possible cardiac 
adverse effects other than heart failure, particularly in patients 
also receiving insulin.28 In August 2006, the FDA received 
GSK’s formal analysis of 42 randomized trials along with data 
from a large observational study. The meta-analysis suggested 
a possible “31% increase in cardiac ischemic events with Vascular Health and Risk Management 2009:5 391
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rosiglitazone,” whereas the observational study showed no such 
increased risk.28,29 In September 2006, the DREAM (Diabetes 
REduction Assessment with ramipril and rosiglitazone Medica-
tion) Trial which was a placebo-controlled trial in pre-diabetic 
patients, the largest randomized study of rosiglitazone, showed 
a not statistically significant increase in risk for myocardial 
infarction (1.2% vs 0.9%; p = 0.2) among over 5000 patients 
treated with rosiglitazone.30 In December 2006, the ADOPT 
(A Diabetes Outcome Progression Trial) study, a trial involving 
diabetic patients showed similar numbers of heart failure and 
ischemic events with rosiglitazone and metformin that were 
higher than those found with glyburide.31 In May 2007, the 
cardiovascular safety of rosiglitazone was brought to center 
stage following the meta-analyses published by Nissen and 
Wolski32 which claimed that rosiglitazone increased the risk for 
myocardial infarction by about 43% and cardiovascular death 
by about 64%. The limitations of this study lead to significant 
discussion. This triggered an unplanned interim analysis of 
the RECORD (Rosiglitazone Evaluated for Cardiac Outcomes 
and Regulation of Glycaemia in Diabetes) trial,33 a prospective 
outcomes study evaluating add-on rosiglitazone to metformin 
or sulfonylurea which showed 217 patients in the rosigli-
tazone group and 202 patients in the control group to have the 
adjudicated primary end point (hazard ratio [HR], 1.08; 95% 
confidence interval [CI]: 0.89–1.31). No statistical difference 
between the two groups could therefore be shown and the final 
analysis should help answer the question on cardiovascular 
safety. Another meta-analysis of rosiglitazone therapy that 
included long-term trials only (duration 12 months) where 
the majority of cardiovascular events were adjudicated showed 
rosiglitazone use to be associated with a similar increase in 
myocardial infarction incidence across all trials (relative risk 
[RR], 1.42; 95% CI: 1.06–1.91; p = 0.02).34 A meta-analyses 
performed by both the manufacturer35 and a Cochrane review36 
had similar conclusions. Finally a meta-analysis by the US 
FDA28 lead to the FDA’s conclusion at the end of July 2007 
that the use of rosiglitazone for the treatment of T2DM was 
associated with a greater risk of myocardial ischemic events 
than placebo, metformin, or sulfonylureas.17 In part, these 
events have lead to a re-evaluation of the relative importance 
of surrogate markers as opposed to hard end point data which 
is imperative to guide clinical decision making.17,37,38
Diabetes and the elderly
Diabetes is an important health condition for the aging popu-
lation. At least 20% of patients over the age of 65 years have 
diabetes, and this number can be expected to grow rapidly 
in the coming decades. Older individuals with diabetes have 
higher rates of premature death, functional disability, and 
coexisting illnesses such as hypertension, CHD, and stroke 
than those without diabetes. Older adults with diabetes are 
also at greater risk than other older adults for several com-
mon geriatric syndromes, such as polypharmacy, depression, 
cognitive impairment, urinary incontinence, injurious falls, 
and persistent pain.7 The care of older adults with diabetes 
is complicated by their clinical and functional heterogeneity. 
In the past, clinical trials of diabetes therapies such as the 
United Kingdom Prospective Diabetes Study (UKPDS) 
systematically excluded patients above the age of 65 years. 
While age restrictions are slowly being raised, clinical trial 
evidence remains sparser in the elderly population. Unless 
the patient population in the clinical trial is representative 
of the intended treatment population results and treatment 
decisions can not simply be extrapolated. The problem with 
extrapolating results from clinical trials into clinical practice 
is twofold. The clinical trial populations have to reflect the 
heterogeneity of the general population of elderly diabetes 
patients. This requires that clinicians extrapolate findings 
from healthier, compliant trial patients to the care of elderly 
patients. Secondly, trial evidence in a younger population can 
not simply be extrapolated to an older population.
Trial evidence in the elderly
Unfortunately the evidence from clinical trials specifically 
focusing on rosiglitazone use in elderly population is sparse 
and relatively limited. For the ADOPT trial, patients between 
the ages of 30 and 75 years were eligible. However, the 
population was not entirely representative of the elderly 
population with the respective means and standard devia-
tions (SD) for the three arms being 56.3 ± 10 (rosiglitazone), 
57.9 ± 9 (metformin) and 56.4 ± 10.2 years (glyburide).31 In 
the RECORD study the respective means and SDs for both 
the rosiglitazone and control arms were 58 ± 8.3 years.33 The 
weighted adjusted mean ages of the 2007 meta-analysis by 
Nissen and Wolski30 were 56.1 (rosiglitazone) and 56.9 years 
(control) group. The mean ages for patients in the DREAM 
trial were 54.6 (rosiglitazone) and 54.8 (placebo) arms.30 All 
these studies are therefore not entirely representative of the 
elderly population.
Two recent studies specifically investigated and 
compared the effects of rosiglitazone and pioglitazone in 
the elderly population. The first was a large population-
based, retrospective cohort study of 159,026 patients 
of 66 years (mean age 75 years). The analysis employed 
a nested case-control approach and concluded that rosi-
glitazone and not pioglitazone had an increased risk of Vascular Health and Risk Management 2009:5 392
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congestive heart failure, acute myocardial infarction, and 
mortality when compared with other combination oral hypo-
glycemic agent treatments.39 The second study included 
another large cohort of 28,361 patients older than 65 years 
who had initiated treatment with either rosiglitazone or 
pioglitazone.40 The study outcomes included all-cause 
mortality, myocardial infarction, stroke, and hospitalization 
for CHF. After adjustment for a large number of patient 
characteristics, a 15% greater mortality among patients 
who initiated therapy with rosiglitazone compared with 
pioglitazone (95% CI: 5%–26%) was demonstrated. Use 
of rosiglitazone was also associated with a 13% greater 
risk of congestive heart failure (95% CI: 1%–26%). No 
differences between the two drugs were found in their rates 
of myocardial infarction or stroke. This is the first study 
known specifically aimed at detecting any differences in 
relative cardiovascular safety between these two TZDs in 
elderly patients. The limitations of these cohort studies are 
primarily due to nonrandomization, less strict adjudication 
of outcomes, and control of adherence to therapy. Unfortu-
nately only sparse information has become available from 
head-to-head comparisons between these two drugs and one 
is therefore restricted to this lower level of evidence. One 
of the few head-to-head studies between rosiglitazone and 
pioglitazone randomized 802 patients with T2DM treated 
by diet alone or monotherapy with an oral hypoglycemic 
agent. The effects these two TZDs had on lipid levels and 
glycemic control were evaluated over a 24-week period.44 
Although the drugs achieved similar glycemic control, 
the study revealed lipid effects that markedly favored 
pioglitazone over rosiglitazone. However, the study was 
clearly not designed or powered to detect differences in 
important long-term clinical outcomes. More so, these data 
can not be simply extrapolated to the elderly population as 
mean ± SD was 55.9 ± 10.5 for the pioglitazone arm and 
56.3 ± 11.3 years for the rosiglitazone arm.
Rosiglitazone versus pioglitazone 
and cardiovascular disease
These two TZDs seem to have disparate effects with respect 
to cardiovascular outcomes. As mentioned, the interim 
analysis of the RECORD trial was reported in 2007 and the 
final analysis is awaited. For pioglitazone, the PROACTIVE 
(PROspective pioglitAzone Clinical Trial In macroVascular 
Events) study, is the only outcomes based study in TZDs to be 
reported thus far.41 This trial included more than 5000 patients 
with diabetes at high risk for macrovascular complications. 
Results of the trial suggested that treatment with pioglitazone 
was beneficial from the cardiovascular standpoint. However, 
significant differences were not observed in the pre-specified 
primary end point (death, myocardial infarction, stroke, 
acute coronary syndrome, leg amputation, or coronary or leg 
revascularization). However, for a secondary end point of 
death, myocardial infarction, or stroke, a statistically signifi-
cant benefit was observed. A meta-analysis of pioglitazone 
investigating pioglitazone treatment which included 19 trials 
involving more than 16,000 patients reported a significant 
reduction in death, myocardial infarction, or stroke occurring 
in 375 of 8554 patients (4.4%) receiving pioglitazone and 450 
of 7836 patients (5.7%) receiving control therapy (HR, 0.82; 
95% CI: 0.72–0.94; p = 0.005).42 It has been argued that these 
findings may have been driven primarily by the PROactive 
trial which lead to a second meta-analysis of 94 trials that 
excluded the PROactive trial. This study concluded that 
pioglitazone was associated with reduced all-cause mortality 
with no relevant effect on nonfatal coronary events.43 The 
reason why these seemingly disparate results between these 
two TZDs may exist, is unclear. It may in part be explained 
by the difference these two drugs have on both lipoprotein 
and apolipoprotein concentrations.44–46 The previously men-
tioned randomized trial of 802 patients with T2DM treated by 
diet alone or monotherapy with an oral hypoglycemic agent 
compared the effects of these two TZDs on lipid levels and 
glycemic control for 24 weeks.44 Pioglitazone was associ-
ated with a reduction in triglycerides whereas rosiglitazone 
increased concentrations. Both medications raised low-den-
sity lipoprotein-cholesterol (LDL-C); however, the increase 
was significantly greater with rosiglitazone compared to 
pioglitazone. Pioglitazone did not significantly change apoli-
poprotein B levels but did reduce LDL particle concentration. 
Conversely, rosiglitazone increased both apolipoprotein B 
and LDL particle concentration. Both medications increased 
high-density lipoprotein cholesterol (HDL-C) with piogli-
tazone having no effect on serum apolipoprotein AI levels, 
but rosiglitazone was associated with a decrease in apolipo-
protein AI levels.44,45 All these changes deem rosiglitazone 
to have a less favorable effect on the lipid profile compared 
to pioglitazone. Furthermore, different PPAR agonists can 
yield markedly different patterns of gene modulation which 
will result in complex and largely unknown differences in 
effects on metabolic pathways.47
TZDs and heart failure
The TZDs have been contraindicated in patients with 
all stages of heart failure (New York Heart Association 
class I–IV) since their approval in Europe by the European Vascular Health and Risk Management 2009:5 393
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Medicines Agency (EMEA)48 in contrast to the Unites States, 
where their use is not contra-indicated among diabetic 
patients in early stages of heart failure (New York Heart 
Association class I–II).49 A teleo-analysis of three random-
ized trials, four controlled observational studies, 28 anec-
dotal case reports/case series, and 214 spontaneous reports 
in a Canadian database reported that both rosiglitazone and 
pioglitazone were associated with an approximate doubling 
of the risk of CHF in patients with type 2 diabetes (OR, 2.1; 
95% CI: 1.08–4.08; p = 0.03).50 This analysis estimated the 
number needed to harm with TZDs, based on an OR of 2.10 to 
would be approximately 50 over a 2.2-year follow-up period. 
This study reported on the ages of the four observational 
studies in 67,382 patients and concluded that the adverse 
effect was not limited to the elderly because 42 of 162 case 
subjects (26%) were aged less than 60 years. Separate meta-
analyses of both rosiglitazone and pioglitazone confirmed 
this increased risk with both rosiglitazone and pioglitazone, 
pointing to a class effect.32,42,50,51
Rosiglitazone and risk of fractures
As recently as 2006 the skeletal effects of TZDs in humans 
were limited to observational studies. The first clinical 
study to report on an increased bone loss with TZD use 
was the Health, Aging, and Body Composition longitudinal 
observational study of older adults.52 The cohort included 
666 diabetic participants with an average age of 73 years. Of 
these, 69 participants reported any TZD use during four years 
of follow-up. Increased bone loss was found in diabetic 
women but not men.
More definitive evidence came after the ADOPT trial 
where it was demonstrated that rosiglitazone increased 
the risk of fractures.31 The trial enrolled 2511 men and 
1840 women and assessed monotherapy failure in recently 
diagnosed drug-naïve type 2 diabetics. The investigators 
found an increased risk of fractures among women in the 
rosiglitazone arm of 1.81 (95% CI: 1.17, 2.80) compared to 
metformin and 2.13 (95% CI: 1.30, 3.51) compared to glybu-
ride. The risk for men was not increased. The risk in women 
was increased for both upper and lower limb fractures. The 
ADOPT trial contained data on self-reported menopausal 
status and baseline use of estrogen-containing hormones. As 
expected, premenopausal women had a lower rate of fracture 
than postmenopausal women. Both pre- and postmenopausal 
groups had an approximate doubling of fracture risk with 
rosiglitazone treatment.
Following this report, the clinical trial database of pio-
glitazone was reviewed by Takeda Pharmaceuticals, the 
manufacturer of pioglitazone.53 The trials databases included 
8100 patients treated with pioglitazone and over 7400 patients 
in the comparison group. The risk for fractures showed a similar 
doubling as reported in the ADOPT study with rosiglitazone 
(1.9 per 100 person years in those using pioglitazone compared 
with a rate of 1.1 per 100 person years in those using placebo 
or an active comparator drug). The increased risk for fractures 
therefore also appears to be a class effect. A recent meta-
analysis which included 10 randomized controlled trials that 
lasted at least 12 months and involved over 13,000 patients, 
found that thiazolidinediones were associated with a 45% 
increase in fractures.54
The mechanism by which this occurs is unclear. Lim-
ited studies measuring bone markers point to reduced bone 
formation with no changes in bone resorption.55,56 The lack 
of bone formation may occur via PPARγ stimulation which 
affects the regulation of the pluripotent mesenchymal stem 
cells stimulating differentiation into adipocytes in preference 
over osteoblasts.57
Conclusion
Clinical trial evidence on rosiglitazone therapy in the elderly 
is limited. The available evidence is mainly related to obser-
vational cohort studies. Outcome evidence for rosiglitazone 
even in the general population is still awaited. As opposed 
to pioglitazone, the current evidence of the cardiovascular 
risk of rosiglitazone is neutral at best with several lower 
graded forms of evidence pointing to cardiovascular harm. 
Even though the data are less than conclusive for a CVD risk 
with rosiglitazone or a CVD benefit with pioglitazone, the 
most recent joint consensus statement from the American 
Diabetes Association and the European Association for 
the Study of Diabetes unanimously advised against using 
rosiglitazone.8 In addition, rosiglitazone is also associated 
with increased risk of fractures and CHF. The effects of the 
thiazolidinedione drug class remain incompletely under-
stood. Contrary to the great promise it held when it came to 
the market some authors now question whether the benefits 
outweigh the risks.58
Similar to all other drugs used to treat diabetes, rosigli-
tazone was approved by drug regulatory bodies based on 
its ability to improve glycemic control, rather than based 
on long-term clinical benefit. Following the occurrences 
with rosiglitazone and other drugs, regulatory authorities 
have now grown more stringent and rely less on surrogate 
markers while demanding more data and more quality data. 
The balance between causing harm and potentially denying a 
patient useful treatment is delicate and the evaluation remains Vascular Health and Risk Management 2009:5 394
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complex. In the meantime clinicians are forced to make 
treatment decisions in the ‘light’ of inconclusive evidence.
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